Individual and group response of treatment with ivacaftor on airway and gut microbiota in people with cf and a s1251n mutation

Maartje I. Kristensen, Karin M. de Winter-De Groot, Gitte Berkers, Mei Ling J.N. Chu, Kayleigh Arp, Sophie Ghijsen, Harry G.M. Heijerman, Hubertus G.M. Arets, Christof J. Majoor, Hettie M. Janssens, Renske van der Meer, Debby Bogaert*, Cornelis K. van der Ent

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

12 Citations (Scopus)
28 Downloads (Pure)


Ivacaftor has been shown to restore the functionality of the S1251N (also known as c.3752G>A) mutated CFTR, which may cause alterations in both airway and gut physiology and micro-environment, resulting in a change of microbiota in these organs. The aim of the present study was to analyze the effects of ivacaftor on the microbial community composition of both airway and gut in subjects with CF carrying one S1251N mutation, using a 16S rRNA gene-based sequencing approach. In 16 subjects with CF, repetitive samples from airways and gut were collected just before, and 2 months after, and, for 8 patients, also 9 and 12 months after, start of ivacaftor. 16S rRNA based sequencing identified 344 operational taxonomical units (OTUs) in a total of 139 samples (35 nasopharyngeal, 39 oropharyngeal, 29 sputum, and 36 fecal samples). Ivacaftor significantly enhanced bacterial diversity and overall microbiota composition in the gut (p < 0.01). There were no significant changes in the overall microbial composition and alpha diversity in upper and lower airways of these patients after ivacaftor treatment. Treatment with ivacaftor induces changes in gut microbiota whereas airway microbiota do not change significantly over time.

Original languageEnglish
Article number350
JournalJournal of Personalized Medicine
Issue number5
Early online date27 Apr 2021
Publication statusPublished - May 2021

Bibliographical note

Publisher Copyright:
© 2021 by the authors. Licensee MDPI, Basel, Switzerland.


Dive into the research topics of 'Individual and group response of treatment with ivacaftor on airway and gut microbiota in people with cf and a s1251n mutation'. Together they form a unique fingerprint.

Cite this